In order to compare autologous bone marrow (BMT) and blood cell transplantation (BCT) in patients with acute myeloid leukemia (AML) in first remission (CR1), we retrospectively reviewed the data of 1393 patients registered to EBMT and undergoing either BCT (n = 100), purged (n = 252) or unpurged (n = 1041) BMT. Hematopoietic recovery was significantly quicker after BCT than after either purged or unpurged BMT. The 2-year leukemia-free survival (LFS), relapse incidence (RI) and overall survival for the entire population of patients were 52 ± 1%, 43 ± 1% and 58 ± 1% and were significantly influenced by FAB subtype (M3 vs other) and the intervals between diagnosis and CR1 or CR1 and transplant. After BCT, LFS and RI were 44 ± 6% and 50 ± 6% and did not differ significantly from that found for unpurged BMT (49 ± 2% and 45 ± 2%; P = NS). However, LFS (57 ± 3%) and RI (37 ± 3%) of patients undergoing purged BMT were significantly different from that found for BCT patients (P = 0.01 and P = 0.006). As some characteristics of patients undergoing BCT or purged BMT differed significantly (age, intervals between diagnosis and CR1 or CR1 and transplant), the better outcome observed for purged BMT over BCT patients needs to be prospectively investigated. Bone Marrow Transplantation (2000) 25, 1115-1119. Keywords: blood cell transplantation; acute myeloid leukemia; purging Autologous stem cell transplantation (ASCT) is increasingly used as treatment of acute myeloid leukemia (AML) in first complete remission (CR1), and several studies (AML 8 EORTC, MRC10 Lancet) although not all have shown its superiority over intensive post-induction chemotherapy.
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Summary:
In order to compare autologous bone marrow (BMT) and blood cell transplantation (BCT) in patients with acute myeloid leukemia (AML) in first remission (CR1), we retrospectively reviewed the data of 1393 patients registered to EBMT and undergoing either BCT (n = 100), purged (n = 252) or unpurged (n = 1041) BMT. Hematopoietic recovery was significantly quicker after BCT than after either purged or unpurged BMT. The 2-year leukemia-free survival (LFS), relapse incidence (RI) and overall survival for the entire population of patients were 52 ± 1%, 43 ± 1% and 58 ± 1% and were significantly influenced by FAB subtype (M3 vs other) and the intervals between diagnosis and CR1 or CR1 and transplant. After BCT, LFS and RI were 44 ± 6% and 50 ± 6% and did not differ significantly from that found for unpurged BMT (49 ± 2% and 45 ± 2%; P = NS). However, LFS (57 ± 3%) and RI (37 ± 3%) of patients undergoing purged BMT were significantly different from that found for BCT patients (P = 0.01 and P = 0.006). As some characteristics of patients undergoing BCT or purged BMT differed significantly (age, intervals between diagnosis and CR1 or CR1 and transplant), the better outcome observed for purged BMT over BCT patients needs to be prospectively investigated. Bone Marrow Transplantation (2000) 25, 1115-1119. Keywords: blood cell transplantation; acute myeloid leukemia; purging Autologous stem cell transplantation (ASCT) is increasingly used as treatment of acute myeloid leukemia (AML) in first complete remission (CR1), and several studies (AML 8 EORTC, MRC10 Lancet) although not all have shown its superiority over intensive post-induction chemotherapy. [1] [2] [3] It has been performed using different conditioning regimens which seem to produce similar results. In the most recent EBMT survey of 2472 patients with AML in first CR, the 5-year disease-free survival and relapse incidence were 43 ± 1% and 49 ± 1% (95% confidence interval) (CI) and the combination of cyclophosphamide and total body irradiation (TBI) was not superior to the use of busulfan combined with either cyclophosphamide or melphalan. 4 The source of stem cells is another factor which could influence the patients' survival. 5, 6 In the studies cited above, as well as in a more recent survey from the IBMTR-ABMTR (unpublished), marrow purging was associated with a significant decrease in the risk of relapse and a substantial prolongation of disease-free survival (but not survival). As no prospective study has either confirmed or refuted these results, marrow purging is still a matter of debate.
Autologous blood stem cell transplantation (BCT) was initiated in patients with AML in the mid-1980s as it was hypothesized that blood cells could be less contaminated by residual leukemic cells than bone marrow and that could lead to a decrease in the relapse incidence. [7] [8] [9] The results in patients transplanted in CR1 have shown that hematopoietic recovery was significantly quicker after BCT than after purged or unpurged BMT. 10, 11 Regarding relapse incidence, retrospective analyses of the results of small series of patients transplanted with blood cells, are not informative. In the different BGMT studies, the risks of relapse and disease-free survival were similar whatever the source of stem cells (blood vs marrow). 11, 12 However, concern has been raised over an increased relapse rate following BCT. [13] [14] [15] In the present study, we have retrospectively reviewed the data of AML patients transplanted in CR1 with purged or unpurged BMT or blood cells and who were referred to the EBMT registry after 1985, when BCT started to be used. The influence of the source of stem cells (blood cells vs marrow) was evaluated using univariate and multivariate analyses, as well as using match-pair analysis.
Patients and methods
Patients
During the 1986-1994 period, 1681 patients were registered to EBMT. They have been transplanted for AML in CR1 using either purged or unpurged marrow or blood stem cells. Their data were collected by a questionnaire and out-come was regularly followed. The data of 1393 patients were complete. They were transplanted using unpurged (n = 1041) or purged marrow (n = 252) or using unpurged blood cells (n = 100). The main characteristics of these patients are indicated in Table 1 . There were some statistical differences between these different groups. The age of patients was statistically greater in patients transplanted with blood cells than using purged (P Ͻ 0.0001) or unpurged marrow (P Ͻ 0.0001). The percentage of patients undergoing BCT for promyelocytic leukemia (M3 type of the FAB classification) was lower than that of patients undergoing purged (P = 0.09) or unpurged BMT (P = 0.02).
The transplant modalities (Table 1 ) also differed: the proportion of patients transplanted with TBI was higher in the BMT than the BCT group. Obviously, the number of cells transplanted was higher in BCT patients than in patients transplanted with purged (P Ͻ 0.0001) or unpurged BMT (P Ͻ 0.0001). The interval between CR1 and transplant was longer for unpurged (P = 0.08) or purged (P = 0.0009) BMT than for BCT. For patients undergoing BCT, stem cell mobilization was done with chemotherapy alone (n = 62), chemotherapy and G-CSF or GM-CSF (n = 15) or growth factors alone (n = 14) (91 patients with available information). The cells were collected after the first consolidation chemotherapy in 21 cases, whereas the other 71 patients underwent leukaphereses after the second or third Table 1 Characteristics of patients according to the origin of stem cells (n = 23) chemotherapy course. Blood cells were not treated ex vivo to decrease the number of residual leukemic cells.
Statistical methods
Leukemia-free survival (LFS) was defined as survival without evidence of leukemia. Transplant-related mortality (TRM) was defined as death while in complete remission; patients were censored at time of relapse or last follow-up. For the relapse rate, patients dying of either direct toxicity of the procedure or any other cause not related to leukemia were censored. All analyses were performed using the BMDP and SPSS statistical packages. Kaplan-Meier curves were calculated using the product limit method.
Comparisons of survival probabilities were performed using the logrank test (Mantel-Cox). Patient-, disease-and treatment-related variables were compared between the two groups (BMT or BCT) using the chi-square statistic for categorical variables and the non-parametric Mann-Whitney test for continuous variables. Variables associated with a P value less than 0.2 and those recognized as potential prognostic factors were included as covariates in multivariate analyses comparing the two groups. Multivariate analysis used the Cox proportional hazard regression model to compare risk of relapse, TRM, LFS and survival between the groups.
Results
Prognostic factors
The 2-year relapse incidence (RI), transplant-related mortality, leukemia-free survival or overall survival (OS) was 43 ± 1%, 10 ± 1%, 51 ± 1% and 58 ± 1%, respectively (95% CI). By univariate analysis, the risk of relapse was significantly influenced by FAB morphology (M3 vs others; P = 0.0001) and the intervals between diagnosis and CR1 (P = 0.0002) and CR1 and transplant (P Ͻ 0.001). RI was not significantly influenced by the age or sex of patients, the WBC count or the type of conditioning regimen ( Table 2 ). The multivariate analysis of these variables indicates that RI was significantly influenced by three factors which were the intervals between diagnosis and CR1, CR1 and transplant and the M3 FAB subtype (Table 3) . TRM was significantly influenced by only two factors (M3 subtype: P = 0.04 and patients' age: P = 0.003). By multivariate analysis, the same factors were found to have a significant influence on TRM (Table 3) .
LFS was significantly influenced by FAB morphology (M3 subtype vs others) (P Ͻ 0.01) and the intervals diagnosis-CR1 (P = 0.0004) or CR1-transplant (P Ͻ 0.001) whereas other variables (initial WBC count, age or sex of patients) had no significant prognostic values on LFS (Table 2) . By multivariate analysis, age, M3 subtype, the interval diagnosis-CR1 and CR1-transplant did significantly influence LFS (Table 3 ). The overall survival was influenced by the age of patients (P = 0.02), M3 subtype (P = 0.02) and the interval diagnosis-CR1 (P = 0.003), and CR1-transplant (P = 0.003) ( Table 3) . 
Results of blood cell transplantation
The results of BCT (TRM, RI, LFS and survival) are indicated in Table 4 and the RI and LFS curves are plotted on Figure 1 . Due to the low number of patients analyzed, we were unable to find any patient-, disease-or transplantrelated characteristics which could influence the outcome of patients. Interestingly, for 92 of the BCT patients for whom it was possible to know the number of consolidation chemotherapy courses given between the date of diagnosis and collection, we found that RI was reduced in patients given more than one course of consolidation, as compared to those given one single course (42 ± 7% vs 65 ± 11%), but the difference did not reach the statistical level of significance. Moreover for the patients who had stem cell collection after mobilization with growth factors (alone or combined with chemotherapy), the TRM, RI, DFS and survival did not differ from that obtained in the other patients (data not shown). 
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Comparison between BCT and purged or unpurged BMT
As shown in Table 4 and Figure 1 , the outcome of patients undergoing BCT or unpurged BMT look similar. RI and LFS were significantly different between BCT and purged BMT (Figure 2 ) but the overall survival did not differ significantly according to the source of stem cells. Interestingly, although hematopoietic recovery was significantly quicker after BCT than after either purged or unpurged BMT (Table 5) , TRM did not differ significantly between BCT or either type of BMT. In order to better define the influence of the source of stem cells on RI, LFS, TRM and survival, we performed a multivariate analysis taking into account the source of stem cells (blood vs purged or unpurged marrow) and the other variables found to significantly influence RI, LFS, TRM and survival. In the group of 1141 patients undergoing BCT or unpurged BMT, we did not find the source of stem cells to have a significant influence on TRM (P = 0.8), RI (P = 0.8), LFS (P = 0.1), and survival (P = 0.8). When purged BMT was compared to BCT, we found that RI and LFS were significantly influenced by the origin of stem cells, but there were no statistical differences between both groups for TRM or survival.
Finally, we performed a match-pair analysis to compare BCT and unpurged BMT. A subgroup of 79 patients undergoing BCT was compared to twice the number of patients undergoing unpurged BMT and matched for significant prognostic factors: age, FAB subtype, intervals between diagnosis and CR1 or CR1 and transplant. The other characteristics of these patients were not statistically different ( Table 6 ). As shown in Table 6 and Figure 3 , there were no significant differences between patients undergoing BCT or unpurged BMT for RI, TRM, DFS or survival. A similar analysis could not be performed to compare BCT and purged patients due to the insufficient number of patients in the registry.
Discussion
This retrospective analysis indicates that the results of BCT and unpurged BMT for AML in first CR are similar. As expected, patients autografted with PB engraft quicker, but Table 6 Results observed in patients undergoing ASCT for AML in CR1 according to the origin of stem cells. Match pair analysis (unpurged grafts)
Blood
Unpurged BMT P value 2y-LFS 47 ± 6% 44 ± 4% 0.9 2y-RI 48 ± 6% 50 ± 4% 0.8 2y-TRM 9 ± 4% 11 ± 2% 0.4 2y-survival 55 ± 6% 56 ± 4% 0.7 with no impact on the transplant-related mortality. The influence of the intervals from diagnosis to CR1 and from CR1 to transplant, as already demonstrated in previous EBMT studies, is found again here, with better outcome for patients rapidly reaching remission and transplanted later. The study does not confirm the hypothesis made by some investigators that the relapse incidence could be higher after BCT than after BMT. Laporte et al 13 have reported four patients transplanted with chemotherapymobilized blood cells and observed that three patients exhibited a very early relapse, a phenomenon that they usually did not observe in patients transplanted with bone marrow. In a non-randomized study, Körbling et al 15 have reported that 14 of the 20 patients transplanted with blood cells have relapsed, contrasting with only 11 of the 23 patients transplanted with purged BM. 15 More recently, Mehta et al 14 reported on four consecutive patients transplanted with blood cells, who exhibited early relapse. As previously hypothesized by Laporte et al, they claimed that the higher number of relapses seen after BCT could be related to the higher number of transplanted cells (containing a higher absolute number of residual leukemic cells) in leukaphereses than in bone marrow. Of possible importance is that the majority of these patients received leukaphereses done immediately following achievement of CR, before any consolidation was applied, with therefore very little in vivo purging. These results were obtained from small series not exceeding 20 patients and thus have to be interpreted very cautiously. In the present EBMT study, 100 patients were analyzed and the outcome of these patients undergoing BCT is similar to that usually reported by different groups on ASCT for AML in first CR (see review in Ref. 1). In a recent study, Schiller et al 16 reported on a series of 59 AML patients in CR1 who were treated with high-dose cytarabine-based consolidation then autologous blood cell transplantation; although only 46 patients could undergo autologous transplantation, the 3-year disease-free survival was 42 ± 14% and similar to that usually published after BMT. Despite all these results, the similarity of BCT and unpurged BMT can only be proven using prospective studies. Such a study is ongoing in the cooperative BGMT group. At that time, 62 patients have been transplanted using blood cells (n = 32) or bone marrow (n = 30) and the actuarial relapse incidence and leukemia-free survival are similar, respectively 49 % ± 19% and 44% ± 20% (RI), 49% ± 19% and 54% ± 19% (LFS), P = 0.88 and P = 0.9.
The results of the comparison of BCT and purged BMT are more difficult to interpret. They indicate that the source of stem cells (purged bone marrow vs blood cells) has a significant influence on RI and DFS. This is not surprising as the results of purged BMT are significantly superior to those of unpurged BMT within the EBMT cooperative group. 1 However, it has to be pointed out that the superiority of purged BMT over unpurged BMT or BCT has not yet been demonstrated prospectively and it cannot be excluded that it could be due to bias in patient selection.
If it cannot be definitively concluded from this retrospective analysis that ex vivo purging could significantly prolong the patients' survival, there are some data suggesting that in vivo purging could decrease the relapse incidence as the patients who had blood cell collection after more than one course of consolidation did better than the others. The difference was not statistically significant when all the patients were considered (see above); however, when the 52 patients who achieved CR1 within less than 37 days (median) after diagnosis were considered (rapid remitters), the relapse incidence was significantly higher in the individuals who had blood cell collection after one single course of consolidation than in the other ones and the difference was statistically significant (Figure 4 ). It is however not possible to discover whether this difference results from additional in vivo purging or corresponds to a selection bias, linked to the patients or to the center. Consequently, this also needs to be adressed prospectively.
